UnitedHealth Group: Buffett Leads A Contrarian Buying Spree

UnitedHealth Group (UNH) shares have rallied, attracting significant contrarian investor interest from Warren Buffett, Michael Burry, and Jim Simons' Renaissance Technologies, signaling a belief that the stock is oversold following recent headwinds including a DOJ probe and CEO changes. While revenue growth remains robust, increased policy benefit payouts, jumping from 1-2% to 7-10% growth, have pressured operating income and margins, yet the company's valuation is now significantly discounted against historical averages. This, combined with reinstated 2025 EPS guidance and a reaffirmed 13-16% long-term growth target, suggests potential upside as the company navigates operational adjustments.

Analysis

UnitedHealth Group (UNH) presents a classic contrarian investment case, attracting notable investors like Warren Buffett, Michael Burry, and Renaissance Technologies following significant stock price declines from its peak near $600. The core tension lies between its operational headwinds and its valuation. On one hand, the company faces substantial challenges, including a U.S. Department of Justice probe, a recent CEO change, and sharp margin compression. Operating income fell 44% quarter-over-quarter in the three months to June, with operating margins contracting from 8.16% to 7.27%. This is directly attributable to a surge in policy benefit payout growth, which has accelerated from a 1-2% range to 7-10%, suggesting a material change in its claims processing practices following public criticism. On the other hand, fundamental metrics suggest these risks may be priced in. Revenue growth remains robust, with premiums growing every quarter this year. Critically, the company has reinstated its 2025 guidance to a net EPS of $24.65 to $25.15 and reaffirmed a long-term earnings growth target of 13% to 16%. Valuation is now at a multi-year low, with the P/E ratio -48% below its five-year average and the EV/Sales multiple at 0.79x, indicating a significant discount that provides a potential margin of safety.

Key Decisions for Investors

• Given the backing of prominent contrarian investors and a valuation at its lowest since 2014, investors could view the current share price as an attractive entry point, betting on a mean reversion and management's ability to navigate current challenges.
• Investors must closely monitor the company's next earnings release for stabilization in operating margins and policy benefit payouts, as the recent 44% drop in quarterly operating income represents the primary risk to the thesis.
• The reinstated 2025 EPS guidance of $24.65-$25.15 and the 13-16% long-term growth target should be used as key performance benchmarks; any negative revisions or adverse developments from the DOJ probe would be significant red flags.
• For income-oriented portfolios, the 2.91% dividend yield provides a tangible return, but its sustainability should be weighed against the ongoing margin pressures and operational uncertainties.